Form 4: Director Richard Glickman Receives enGene Stock Options
Statement of Changes in Beneficial Ownership
Director Richard M. Glickman was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity compensation arrangement.
Summary
- Director Richard M. Glickman acquired 31,000 stock options in enGene Therapeutics Inc. (ENGN).
- The options have an exercise price of $1.75 per share.
- The grant date for the transaction was June 16, 2026.
- The options are set to expire on June 16, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future dilution of existing shareholders upon the exercise of these options.
Risks
- Market volatility affecting the value of the underlying common shares.
- Performance risk associated with the company's ability to meet milestones required for share price appreciation.
Future Outlook
The options vest fully on the earlier of the first anniversary of the vesting commencement date (June 9, 2027) or the company's 2027 annual meeting of shareholders.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate development milestones.
Comparison to Industry Standards
- The grant of stock options to directors is consistent with standard corporate governance practices for small-cap biotech firms.
- The vesting schedule tied to annual meetings is a common mechanism to ensure director retention and engagement.
Stakeholder Impact
- Minor potential dilution for existing shareholders if options are exercised.
Next Steps
- Vesting of options on June 9, 2027, or the 2027 annual meeting of shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Vesting commencement date for the granted stock options. |
| 06/16/2026 | Transaction date of the option grant. |
| 06/17/2026 | Filing date of the Form 4. |
| 06/16/2036 | Expiration date of the granted stock options. |
Keywords
enGene Therapeutics, ENGN, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.